Drug intelligence / Profile preview

JHM09

Development stage: Preclinical
Lead developer: JHM Biopharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Injection, Topical

Overview

JHM09 is a recombinant Type III human collagen developed by JHM Biopharmaceutical (Hangzhou) Co., Ltd. (JHM Group) as a Class III medical device. It is a full-length protein that precisely matches the natural sequence of human Type III collagen and maintains its characteristic triple helical structure. The product is manufactured using a proprietary cell factory biosynthesis process that emulates natural protein production. JHM Group has completed process development and scale-up activities, establishing a commercial-scale manufacturing facility for the product. As a Class III medical device, JHM09 is intended for high-risk applications such as tissue repair, regeneration, or aesthetic dermatology.

Other names: recombinant Type III human collagen

Beyond the preview

Go deeper on JHM09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JHM09.

Explore the full profile